Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2025 07:02 ET | Source: Ocugen

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
June 12, 2025 09:11 ET | Source: Spherix Global Insights

Hematologists Set the Stage for Market Disruption as Next-Gen Hemophilia Therapies Gain Traction

EXTON, PA, June 12, 2025 (GLOBE NEWSWIRE) -- As the hemophilia landscape continues to transform, new research from Spherix Global Insights reveals a market on the cusp of significant evolution...
June 12, 2025 07:21 ET | Source: Research and Markets

Gene Therapy Collaboration and Licensing Deals Report and Directory 2025: Explore the Financials Behind 787 Gene Therapy Licensing Deals from 2016-2025

Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering.This report contains a...
June 11, 2025 08:00 ET | Source: uniQure Inc.

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer

~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading...
June 11, 2025 07:30 ET | Source: Ocugen

Ocugen To Present at BIO International Convention 2025

MALVERN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
June 05, 2025 07:02 ET | Source: Ocugen

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net...
June 03, 2025 05:47 ET | Source: Research and Markets

Gene Editing Market Research Report 2025-2029 - Biotech Leaders Drive Innovation as Gene Editing Becomes Key to Sustainable Solutions

Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Gene Editing Markets 2025-2029 by Application, Technology, Place, Industry and Product with Executive & Consultant Guides" report has been added to...
June 02, 2025 04:19 ET | Source: Research and Markets

Cell & Gene Therapy Bioanalytical Testing Services Market Forecast Report to 2030 | CRISPR-Cas9 and Single-Cell Analysis Revolutionizing Bioanalytical Testing in Cell Therapies

Dublin, June 02, 2025 (GLOBE NEWSWIRE) -- The "Cell & Gene Therapy Bioanalytical Testing Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been...
May 30, 2025 04:12 ET | Source: Research and Markets

Cell & Gene Therapies in Dermatology Disorders | Develop Robust In-Licensing Strategies in the Face of GI CGT Market Changes

Dublin, May 30, 2025 (GLOBE NEWSWIRE) -- The "Cell & Gene Therapies in Dermatology Disorders: Therapeutic Analysis" report has been added to ResearchAndMarkets.com's offering.Currently, there...
May 29, 2025 07:05 ET | Source: uniQure Inc.

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy...

Next Page keyboard_arrow_right